Physician profile
Gerald Simon
NPI 1861450330
$9,246.50
in general payments reported to CMS, 2019-2025
53 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $1,246 · 2021: $1,370 · 2022: $1,691 · 2023: $1,356 · 2024: $1,092 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,848 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,848.07 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,009.63 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $880.77 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $704.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $681.84 | 2019-2025 | |
| Abbvie INC. | $658.57 | 2020-2025 | Linzess, Viberzi, Vraylar |
| Lilly USA, LLC | $627.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $497.70 | 2019-2022 | |
| Pfizer INC. | $379.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $319.10 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $249.25 | 2019-2024 | Spravato |
| Dexcom, INC. | $237.95 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $231.07 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.61 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $208.98 | 2021-2025 | Eliquis, Camzyos |
| Nestle Healthcare Nutrition INC. | $178.18 | 2020-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.